In a growing trend, some users of GLP-1 medications are hailing their results with microdosing, taking ...

With one in eight adults taking drugs like Ozempic and Mounjaro, emerging evidence shows that the medication has potential to ...

Something profound is happening in Canada’s food economy, and most people haven’t quite grasped it yet. It’s not a new grocer ...

After a long, exhausting day at work, sometimes the last thing you want to do is cook a big meal, not to mention deal with ...

Meanwhile, Vancouver researcher, Dr. Tae-Ho Kim, was recognized with a Mitacs Innovation Award — Outstanding Innovation, for his groundbreaking work designing a self-powered continuous blood pressure ...

Discover why Viking Therapeutics, Inc. surged 50% as GLP-1 market buzz and strong VK2735 results renew investor optimism.

Novo Nordisk, whose shares have stumbled this year, on Tuesday announced a positive trial result for a weight-loss drug in ...

The pharma giant said amycretin led to weight loss and diabetes reductions in both injection and pill versions.

Novo Nordisk said on Tuesday its experimental obesity drug, amycretin, showed statistically significant weight loss of up to 14.5% at 36 weeks in patients with type 2 diabetes in a mid-stage study.

Trial participants who used eloralintide, a new weight loss medication that, instead of focusing on the hormone GLP-1, ...

The Trump administration is making a significant effort to reduce the cost of weight loss drugs. Its agreement with ...

Novo and Lilly just slashed prices on GLP-1 weight-loss drugs that recently cost over $1,000 a month. What happened?